Post Profile
Adding Drug to Standard Chemotherapy Provides No Survival Benefit for Older Lung Cancer Patients
Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) - an approach approved by the FDA in 2006 - did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.
read more
Non-Small Cell Lung Cancer Patients Benefit From Less Toxic Combination Of Erlotinib And Bevacizumab
The standard treatment for patients with advanced non-small cell lung cancer (NSCLC) is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now, Fox Chase Cance... Read Post
New Drug Approved For Treatment Of Non Small Cell Lung Cancer In Specific Patient Population
Lung Cancer Alliance (LCA) applauds the Food and Drug Administration (FDA) approval of Xalkori (crizotinib) with non-small cell lung cancer (NSCLC) who are ALK positive. The drug was approved based on data from two clinical trials, ... Read Post
Bevacizumab Doesn't Improve Survival In Some Older Lung Cancer Patients
A study published in the April 18 issue of JAMA, reveals that Medicare insured non-small cell lung cancer (NSCLC) patients aged 65+, who received bevacizumab, in addition to the standard chemotherapy regimen carboplatin and paclitax... Read Post